基石藥業(02616.HK)：avapritinib可使PDGFRA D842V突變型GIST患者達到持久臨牀獲益，研究發表於“柳葉刀腫瘤學”
格隆匯7月6日丨基石藥業－Ｂ(02616.HK)發佈公告，公司的合作伙伴 Blueprint Medicines Corporation (Blueprint Medicines，納斯達克股份代號：BPMC)於6月29日宣佈，“柳葉刀腫瘤學”發表了 NAVIGATOR 臨牀試驗結果，資料顯示 avapritinib 用於 PDGFRA D842V 突變型晚期胃腸間質瘤(“GIST”)患者，24個月的總生存(「OS」)率達到 81%，且耐受性良好。該研究報告2020年6月29日正式發表於“柳葉刀腫瘤學”，文章標題為“avapritinib 治療晚期 PDGFRA D842V 突變型胃腸間質瘤(NAVIGATOR)：一項多中心、開放標籤的一期研究”。
Blueprint Medicines 已與基石藥業達成獨家合作及授權授權合約，在中國內地和香港特別行政區、澳門特別行政區及中國台灣推進 avapritinib、fisogatinib 和 pralsetinib 的研發和商業化。 Blueprint Medicines 將保留以上相關產品在全球其他國家/地區的研發和商業化權利。
有關重點消息包括：發表於“柳葉刀腫瘤學”上的文章報告了 NAVIGATOR 試驗的有效性和安全性結果，包括劑量遞增階段的所有患者，以及擴展階段的 PDGFRA D842V 突變型 GIST 亞組患者。療效分析人羣包括56例 PDGFRA D842V 突變型 GIST 患者。安全性分析人羣包括82例患者，其中包括劑量遞增研究階段的26例非 PDGFRA D842V 突變型 GIST 患者。所有資料截止日期為2018年11月16日；
資料顯示，接受 avapritinib 治療的 PDGFRA D842V 突變型 GIST 患者中，總體緩解率達到 88%(95% CI：76%-95%)，有 9%的患者達到完全緩解。avapritinib 治療在這一患者人羣中顯示出了持久的臨牀獲益，12個月持續緩解率為 70%(95% CI： 54%-87%)，12個月無進展生存率為 81%(95% CI：69%-93%)，24個月總生存率為 81%(95% CI：67%-94%)；
avapritinib 總體耐受性良好，研究中報告的治療相關不良事件大部分為一級或二級。最常見的治療相關不良事件為噁心、疲乏、腹瀉、眶周水腫、貧血、食慾減退、嘔吐和記憶力減退。40%的患者出現認知障礙，大多數報告的事件為一級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
